

Yusuf Menda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1221468/publications.pdf>

Version: 2024-02-01

90
papers

4,139
citations

147801

31
h-index

118850

62
g-index

92
all docs

92
docs citations

92
times ranked

4229
citing authors

#	ARTICLE	IF	CITATIONS
1	The Impact of Radiopharmaceutical Therapy on Renal Function. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 467-474.	4.6	9
2	Radiopharmaceuticals for Neuroendocrine Tumors. <i>Seminars in Radiation Oncology</i> , 2021, 31, 60-70.	2.2	10
3	Addition of ¹³¹ I-MIBG to PRRT (⁹⁰ Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1274-1277.	5.0	11
4	A Framework for Patient-Centered Pathways of Care for Radiopharmaceutical Therapy: An ASTRO Consensus Document. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 913-922.	0.8	12
5	Multiparametric magnetic resonance imaging and positron emission tomography findings in neurodegenerative diseases: Current status and future directions. <i>Neuroradiology Journal</i> , 2021, 34, 263-288.	1.2	4
6	Potential for Increasing Uptake of Radiolabeled ⁶⁸ Ga-DOTATOC and ¹²³ I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 632-641.	1.0	9
7	The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2020, 49, 1-33.	1.1	226
8	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2020, 49, 863-881.	1.1	88
9	Polyazamacrocycle Ligands Facilitate ⁸⁹ Zr Radiochemistry and Yield ⁸⁹ Zr Complexes with Remarkable Stability. <i>Inorganic Chemistry</i> , 2020, 59, 17473-17487.	4.0	13
10	Association of gallbladder hyperkinesia with acalculous chronic cholecystitis: A case-control study. <i>Surgery</i> , 2020, 168, 800-808.	1.9	8
11	Diagnostic Performance of PET and Perfusion-Weighted Imaging in Differentiating Tumor Recurrence or Progression from Radiation Necrosis in Posttreatment Gliomas: A Review of Literature. <i>American Journal of Neuroradiology</i> , 2020, 41, 1550-1557.	2.4	15
12	Prospective Analysis of the Impact of ⁶⁸ Ga-DOTATOC Positron Emission Tomography-Computerized Axial Tomography on Management of Pancreatic and Small Bowel Neuroendocrine Tumors. <i>Pancreas</i> , 2020, 49, 1033-1036.	1.1	6
13	Comparison of T ₁ Rho MRI, Glucose Metabolism, and Amyloid Burden Across the Cognitive Spectrum: A Pilot Study. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020, 32, 352-361.	1.8	4
14	Nuclear Imaging of Neuroendocrine Tumors. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 209-221.	1.5	10
15	Regional Myocardial Remodeling Characteristics Correlates With Cardiac Events in Sarcoidosis. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 52, 499-509.	3.4	3
16	NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of ¹⁷⁷ Lu-DOTATATE Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 222-227.	5.0	77
17	Potential False-Positive Meckel's Scan Caused by Umbilical Ornamentation. <i>Clinical Nuclear Medicine</i> , 2020, 45, 735-737.	1.3	2
18	Giant vertebral hemangioma masquerading as aggressive tumor: Tc-99m tagged RBC scan can help to solve the diagnostic conundrum!. <i>Radiology Case Reports</i> , 2019, 14, 1360-1363.	0.6	7

#	ARTICLE	IF	CITATIONS
19	FLT PET Radiomics for Response Prediction to Chemoradiation Therapy in Head and Neck Squamous Cell Cancer. <i>Tomography</i> , 2019, 5, 161-169.	1.8	28
20	Clinical Utility of Pretreatment and 3-Month 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Standardized Uptake Value in Predicting and Assessing Recurrence in T3-T4 Laryngeal Carcinoma Treated With Definitive Radiation. <i>Annals of Otolaryngology and Rhinology</i> , 2019, 128, 595-600.	1.1	4
21	Early Phase PIB-PET as a Surrogate for Global and Regional Cerebral Blood Flow Measures. <i>Journal of Neuroimaging</i> , 2019, 29, 85-96.	2.0	6
22	⁹⁰ Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1692-1698.	5.0	36
23	Technical Note: Single time point dose estimate for exponential clearance. <i>Medical Physics</i> , 2018, 45, 2318-2324.	3.0	53
24	Posterior Reversible Encephalopathy Syndrome on 18F-FDG PET/CT in a Pediatric Patient With Burkitt's Lymphoma. <i>Clinical Nuclear Medicine</i> , 2018, 43, 195-198.	1.3	5
25	Localization of Unknown Primary Site with ⁶⁸ Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1054-1057.	5.0	29
26	Automated cassette-based production of high specific activity [²⁰³ Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer. <i>Applied Radiation and Isotopes</i> , 2017, 127, 52-60.	1.5	36
27	The Surgical Management of Small Bowel Neuroendocrine Tumors. <i>Pancreas</i> , 2017, 46, 715-731.	1.1	262
28	Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors. , 2017, , 411-427.		0
29	Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors. <i>Pancreas</i> , 2017, 46, 151-156.	1.1	34
30	Identification of primary tumors in patients presenting with metastatic gastroenteropancreatic neuroendocrine tumors. <i>Surgery</i> , 2017, 161, 272-279.	1.9	35
31	Safety and accuracy of Ga-DOTATOC PET/CT in children and young adults with solid tumors. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 7, 228-235.	1.0	7
32	Using [¹⁸ F]Fluorothymidine Imaged With Positron Emission Tomography to Quantify and Reduce Hematologic Toxicity Due to Chemoradiation Therapy for Pelvic Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 228-239.	0.8	28
33	Preliminary Investigation of Cerebral Blood Flow and Amyloid Burden in Veterans With and Without Combat-Related Traumatic Brain Injury. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2016, 28, 89-96.	1.8	18
34	Incidental Meningioma Detected on 18F-Fluoride With PET/CT During Initial Staging for Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2015, 40, 596-597.	1.3	8
35	Change of Maximum Standardized Uptake Value-Slope in Dynamic Triphasic [¹⁸ F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Distinguishes Malignancy From Postirradiation Inflammation in Head-and-Neck Squamous Cell Carcinoma: A Prospective Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 472-479.	0.8	19
36	Frontal hypometabolism in elderly breast cancer survivors determined by [¹⁸ F]fluorodeoxyglucose (FDG) positron emission tomography (PET): a pilot study. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 587-594.	2.7	30

#	ARTICLE	IF	CITATIONS
37	Dependency of cardiac rubidium-82 imaging quantitative measures on age, gender, vascular territory, and software in a cardiovascular normal population. <i>Journal of Nuclear Cardiology</i> , 2015, 22, 72-84.	2.1	28
38	Feasibility and advantage of adding 131I-MIBG to 90Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors. <i>EJNMMI Research</i> , 2014, 4, 38.	2.5	12
39	Current Management of Radioiodine Sialadenitis. <i>Current Otorhinolaryngology Reports</i> , 2014, 2, 70-84.	0.5	8
40	Limitations of somatostatin scintigraphy in primary small bowel neuroendocrine tumors. <i>Journal of Surgical Research</i> , 2014, 190, 548-553.	1.6	23
41	Spatial mapping of functional pelvic bone marrow using FLT PET. <i>Journal of Applied Clinical Medical Physics</i> , 2014, 15, 129-136.	1.9	29
42	The Value of Preoperative Imaging in Small Bowel Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , 2013, 20, 1912-1917.	1.5	32
43	Repeatability of Gallium-68 DOTATOC Positron Emission Tomographic Imaging in Neuroendocrine Tumors. <i>Pancreas</i> , 2013, 42, 937-943.	1.1	23
44	PET Imaging During Radiotherapy of Head and Neck Cancer. <i>Journal of Nuclear Medicine</i> , 2013, 54, 497-498.	5.0	3
45	Reply: Peptide Receptor Radionuclide Therapy in the United States. <i>Journal of Nuclear Medicine</i> , 2012, 53, 840-840.	5.0	0
46	Cerebral blood flow and neuropsychological functioning in elderly vascular disease patients. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2012, 34, 220-225.	1.3	17
47	American Thoracic Society Documents: An Official American Thoracic Society/Society of Thoracic Radiology Clinical Practice Guideline—Evaluation of Suspected Pulmonary Embolism in Pregnancy. <i>Radiology</i> , 2012, 262, 635-646.	7.3	121
48	New Tracers PET in Head and Neck Squamous Cell Carcinoma. <i>PET Clinics</i> , 2012, 7, 431-441.	3.0	2
49	Functional Imaging in the Assessment of Normal Tissue Injury Following Radiotherapy. , 2012, , 195-215.		0
50	A methodology for incorporating functional bone marrow sparing in IMRT planning for pelvic radiation therapy. <i>Radiotherapy and Oncology</i> , 2011, 99, 49-54.	0.6	39
51	³ â€™-deoxy- ³ â€™-[¹⁸ F]fluorothymidine PET Quantification of Bone Marrow Response to Radiation Dose. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 888-893.	0.8	27
52	An Official American Thoracic Society/Society of Thoracic Radiology Clinical Practice Guideline: Evaluation of Suspected Pulmonary Embolism In Pregnancy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 1200-1208.	5.6	182
53	Radiopeptide Imaging and Therapy in the United States. <i>Journal of Nuclear Medicine</i> , 2011, 52, 56S-63S.	5.0	73
54	FDG PET Imaging of Head and Neck Cancers. <i>Methods in Molecular Biology</i> , 2011, 727, 21-31.	0.9	2

#	ARTICLE	IF	CITATIONS
55	PET-CT scans in recurrent or persistent differentiated thyroid cancer: Is there added utility beyond conventional imaging?. <i>Surgery</i> , 2010, 148, 1082-1090.	1.9	11
56	⁹⁰ Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide. <i>Journal of Clinical Oncology</i> , 2010, 28, 1652-1659.	1.6	299
57	Stability of ¹⁸ F-Fluorothymidine Standardized Uptake Values in Head and Neck Cancer Over Time. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010, 25, 361-363.	1.0	3
58	Phase I Trial of ⁹⁰ Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1524-1531.	5.0	72
59	Investigation of the pharmacokinetics of ¹⁸ F-fluorothymidine uptake in the bone marrow before and early after initiation of chemoradiation therapy in head and neck cancer. <i>Nuclear Medicine and Biology</i> , 2010, 37, 433-438.	0.6	19
60	Clinical Significance of Postradiotherapy [18F]-Fluorodeoxyglucose Positron Emission Tomography Imaging in Management of Head-and-Neck Cancer—A Long-Term Outcome Report. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 9-14.	0.8	108
61	Kinetic Analysis of ¹⁸ F-Fluorothymidine (18F-FLT) in Head and Neck Cancer Patients Before and Early After Initiation of Chemoradiation Therapy. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1028-1035.	5.0	77
62	A Comparison Between Diagnostic I-123 and Posttherapy I-131 Scans in the Detection of Remnant and Locoregional Thyroid Disease. <i>Clinical Nuclear Medicine</i> , 2009, 34, 745-748.	1.3	10
63	Radionuclide Cisternography in Detecting Cerebrospinal Fluid Leak in Spontaneous Intracranial Hypotension. <i>Clinical Nuclear Medicine</i> , 2009, 34, 410-416.	1.3	16
64	Single Photon Emission Computed Tomography (SPECT) Should be Routinely Performed for the Detection of Parathyroid Abnormalities Utilizing Technetium-99m Sestamibi Parathyroid Scintigraphy. <i>Clinical Nuclear Medicine</i> , 2009, 34, 651-655.	1.3	61
65	Gastroenteropancreatic neuroendocrine tumors in children and young adults. <i>Pediatric Radiology</i> , 2008, 38, 251-259.	2.0	34
66	Somatostatin receptor scintigraphy in surveillance of pediatric brain malignancies. <i>Pediatric Blood and Cancer</i> , 2008, 50, 561-566.	1.5	13
67	Posttreatment FDG-PET Uptake in the Supraglottic and Glottic Larynx Correlates With Decreased Quality of Life After Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 386-392.	0.8	30
68	Tc-99m Red Blood Cell Imaging in a Patient With Blue Rubber Bleb Nevus Syndrome. <i>Clinical Nuclear Medicine</i> , 2008, 33, 374-376.	1.3	10
69	Pathology and FDG PET Correlation of Residual Lymph Nodes in Head and Neck Cancer After Radiation Treatment. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 264-270.	1.3	63
70	Minimally Invasive Parathyroidectomy and Preoperative MIBI Scans: Correlation of Gland Weight and Preoperative PTH. <i>Journal of the American College of Surgeons</i> , 2007, 205, S38-S44.	0.5	53
71	Use of Lymphoscintigraphy With SPECT/CT for Sentinel Node Localization in a Case of Vaginal Melanoma. <i>Clinical Nuclear Medicine</i> , 2006, 31, 201-202.	1.3	29
72	Potential increased tumor-dose delivery with combined ¹³¹ I-MIBG and ⁹⁰ Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model. <i>Journal of Nuclear Medicine</i> , 2006, 47, 660-7.	5.0	17

#	ARTICLE	IF	CITATIONS
73	Comparison of cardiac to hepatic uptake of ^{99m}Tc -tetrofosmin with and without adenosine infusion to predict the presence of haemodynamically significant coronary artery disease. <i>Nuclear Medicine Communications</i> , 2005, 26, 513-518.	1.1	3
74	The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 991-999.	0.8	189
75	Response Assessment of Aggressive Non-Hodgkin's Lymphoma by Integrated International Workshop Criteria and Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography. <i>Journal of Clinical Oncology</i> , 2005, 23, 4652-4661.	1.6	364
76	Update on ^{18}F -Fluorodeoxyglucose/Positron Emission Tomography and Positron Emission Tomography/Computed Tomography Imaging of Squamous Head and Neck Cancers. <i>Seminars in Nuclear Medicine</i> , 2005, 35, 214-219.	4.6	91
77	Positron Emission Tomography/Computed Tomography Imaging of Head and Neck Tumors: An Atlas. <i>Seminars in Nuclear Medicine</i> , 2005, 35, 220-252.	4.6	12
78	MIBG and somatostatin receptor analogs in children: current concepts on diagnostic and therapeutic use. <i>Journal of Nuclear Medicine</i> , 2005, 46 Suppl 1, 55S-61S.	5.0	13
79	Effects of Intravenous Amino Acid Administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTherâ,ç]) Treatment. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 35-41.	1.0	19
80	The Utility of ^{99m}Tc Depreotide Compared With F-18 Fluorodeoxyglucose Positron Emission Tomography and Surgical Staging in Patients With Suspected Non-small Cell Lung Cancer. <i>Chest</i> , 2004, 125, 494-501.	0.8	41
81	The role of post-radiation therapy fdg pet in prediction of necessity for post-radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 1001-1010.	0.8	128
82	Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: A preliminary report. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 1410-1418.	0.8	90
83	A 36-Year Retrospective Analysis of the Efficacy and Safety of Radioactive Iodine in Treating Young Graves' Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4229-4233.	3.6	187
84	^{99m}Tc -depreotide tumour uptake in patients with non-Hodgkin's lymphoma. <i>Nuclear Medicine Communications</i> , 2004, 25, 839-843.	1.1	16
85	Assessment of Hepatic Toxicity from Treatment with ^{90}Y -SMT 487 (OctreoTherâ,ç) in Patients with Diffuse Somatostatin Receptor Positive Liver Metastases. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2003, 18, 581-588.	1.0	14
86	Evaluating the clinical effectiveness of ^{90}Y -SMT 487 in patients with neuroendocrine tumors. <i>Journal of Nuclear Medicine</i> , 2003, 44, 1556-60.	5.0	37
87	Can FDG-PET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer?. <i>Annals of Thoracic Surgery</i> , 2002, 73, 394-402.	1.3	124
88	Somatostatin receptor imaging of non-small cell lung cancer with ^{99m}Tc depreotide. <i>Seminars in Nuclear Medicine</i> , 2002, 32, 92-96.	4.6	80
89	FDG Positron Emission Tomographic Imaging of Pseudo-pseudo Tumor. <i>Clinical Nuclear Medicine</i> , 2002, 27, 445-446.	1.3	3
90	Efficacy and Safety of Repeated Samarium-153 Lexidronam Treatment in a Patient with Prostate Cancer and Metastatic Bone Pain. <i>Clinical Nuclear Medicine</i> , 2000, 25, 698-700.	1.3	30